Please assess the completion status of the following clinical trial:

Trial Title: MSB11022 in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male subjects and healthy female subjects of non-childbearing potential aged 18 to 55 years, inclusive.~* Other protocol defined inclusion criteria could apply.~Exclusion Criteria:~* Concurrent or history infections such as opportunistic infections, including sepsis, pneumonia, and fungal infection.~* Individuals with history of tuberculosis or diagnosed with tuberculosis by interview, chest X-ray examination, or interferon-gamma release assay.~* Concurrent or history of demyelinating disease (multiple sclerosis, etc.).~* Concurrent or history of congestive cardiac failure.~* Concurrent or history of allergic symptoms such as asthma bronchial, drug-induced rash, and urticaria, which, in the judgment of the investigator, may affect participation in this clinical study.~* Concurrent or history of cardiac, hepatic, renal, gastrointestinal, respiratory, and/or hematological function disorders, which, in the judgment of the investigator or any of the sub investigators, may affect participation in this clinical study.~* Other protocol defined exclusion criteria could apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- MSB11022 (Type: EXPERIMENTAL): None
- US-licensed Humira (Type: ACTIVE_COMPARATOR): None
- EU-approved Humira (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).